847684-97-3Relevant academic research and scientific papers
GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS
-
Paragraph 00647-00648, (2016/07/05)
The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7- nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.
Highly convergent synthesis of a rebeccamycin analog with benzothioeno(2,3-a)pyrrolo(3,4-c)carbazole as the aglycone
Wang, Jianji,Soundarajan, Nachimuthu,Liu, Nian,Zimmermann, Kurt,Naidu, B. Narasimhulu
, p. 907 - 910 (2007/10/03)
A highly convergent, scalable synthesis of the rebeccamycin analog 2 was demonstrated in seven steps and 31% overall yield based on the N-protected building block dibromomaleimide 7. The practical synthesis of other two building blocks, 5,6-difluoro-3-ben
Design and Synthesis of a Fluoroindolocarbazole Series as Selective Topoisomerase I Active Agents. Discovery of Water-Soluble 3,9-Difluoro-12,13-dihydro-13-[6-amino-β-D-glucopyranosyll]-5H,13H-benzo[b] -thienyl[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (BMS-251873) with Curative Antitumor Activity against Prostate Carcinoma Xenograft Tumor Model
Balasubramanian, Balu N.,St. Laurent, Denis R.,Saulnier, Mark G.,Long, Byron H.,Bachand, Carol,Beaulieu, Francis,Clarke, Wendy,Deshpande, Milind,Eummer, Jeffrey,Fairchild, Craig R.,Frennesson, David B.,Kramer, Robert,Lee, Frank Y.,Mahler, Mikael,Martel, Alain,Naidu, B. Narasimhulu,Rose, William C.,Russell, John,Ruediger, Edward,Solomon, Carola,Stoffan, Karen M.,Wong, Henry,Zimmermann, Kurt,Vyas, Dolatrai M.
, p. 1609 - 1612 (2007/10/03)
A series of fluoroindolocarbazoles were studied with respect to their topoisomerase I activity, cytotoxicity, selectivity, and in vivo antitumor activity. Emerging from this series was BMS-251873, a potential clinical candidate possessing a robust pharmacological profile including curative antitumor activity against prostate carcinoma.
